Final NICE backing for MabThera in rare condition PMLiVE The National Institute for Heath and Care Excellence (NICE) issued final guidance this week that gave the green light for MabThera (rituximab) to treat adults with a rare condition known as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. |
